SCHEMBL4282790

SCHEMBL4282790

O=C(c1ncn([C@H]2CCCC[C@@H]2N(CCF)C(=O)O)c1-c1ccccc1)N1CCN(Cc2ccccc2)C[C@H]1Cc1cc(F)cc(F)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 4/20 0.37
CA2 P00918 4/20 0.37
CA4 P22748 4/20 0.37
CA9 Q16790 4/20 0.37
DPP4 P27487 1/20 0.35
DPP7 Q9UHL4 1/20 0.35
EGFR P00533 1/20 0.34
ROCK1 Q13464 1/20 0.33
SIGMAR1 Q99720 1/20 0.33
SCD5 Q86SK9 1/20 0.32
DRD2 P14416 1/20 0.31
DRD4 P21917 1/20 0.31
ALDH1A1 P00352 1/20 0.31
TACR2 P21452 1/20 0.31
TACR1 P25103 1/20 0.31
BCHE P06276 1/20 0.31
DAGLA Q9Y4D2 1/20 0.30
CHRM2 P08172 1/20 0.30
CHRM1 P11229 1/20 0.30
CYP2D6 P10635 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4289524 0.89 CA1 (0.43) CA1CA2CA4CA9DPP4
SCHEMBL4281507 0.87 CA1 (0.35) CA1CA2CA4CA9DPP4
SCHEMBL4284624 0.86 CA1 (0.41) CA1CA2CA4CA9DPP4
SCHEMBL4293929 0.86 CA1 (0.42) CA1CA2CA4CA9DPP4
SCHEMBL4296440 0.85 CA1 (0.40) CA1CA2CA4CA9DPP4
SCHEMBL4286453 0.84 CA1 (0.39) CA1CA2CA4CA9DPP4
SCHEMBL4287968 0.83 CA1 (0.33) CA1CA2CA4CA9DPP4
SCHEMBL13705173 0.80 CA1 (0.36) CA1CA2CA4CA9DPP4
SCHEMBL4281061 0.80 CA1 (0.41) CA1CA2CA4CA9DPP4
SCHEMBL4752441 0.79 CA1 (0.36) CA1CA2CA4CA9DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090227560-A1 Substituted imidazole compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-09-10 US disclosed
US-20090156612-A1 Substituted imidazole compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156612-A1 Substituted imidazole compound and use thereof REN, ACE, AGT CA1 2275/4885CA2 218/4885CA4 296/4885
US-20090227560-A1 Substituted imidazole compound and use thereof REN, ACE, AGT CA1 2275/4885CA2 218/4885CA4 296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.